Investigational Drug Information for Obicetrapib
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the drug development status for Obicetrapib?
Obicetrapib is an investigational drug.
There have been 8 clinical trials for Obicetrapib.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Atherosclerosis. The leading clinical trial sponsors are NewAmsterdam Pharma and [disabled in preview].
There are three US patents protecting this investigational drug and eighty-nine international patents.
Summary for Obicetrapib
| US Patents | 3 |
| International Patents | 89 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 20 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2022-02-01) |
| Vendors | 12 |
Recent Clinical Trials for Obicetrapib
| Title | Sponsor | Phase |
|---|---|---|
| Randomized Study in Patients With HeFH to Evaluate Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | NewAmsterdam Pharma | Phase 3 |
| A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | NewAmsterdam Pharma | Phase 2 |
| Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | NewAmsterdam Pharma | Phase 2 |
Clinical Trial Summary for Obicetrapib
Top disease conditions for Obicetrapib
Top clinical trial sponsors for Obicetrapib
US Patents for Obicetrapib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Obicetrapib | ⤷ Sign Up | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | DEZIMA PHARMA B.V. (Naarden, NL) | ⤷ Sign Up |
| Obicetrapib | ⤷ Sign Up | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors | DEZIMA PHARMA B.V. (NL) | ⤷ Sign Up |
| Obicetrapib | ⤷ Sign Up | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | DEZIMA PHARMA BV (NL) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Obicetrapib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Obicetrapib | Argentina | AR101509 | 2034-08-12 | ⤷ Sign Up |
| Obicetrapib | Australia | AU2015302407 | 2034-08-12 | ⤷ Sign Up |
| Obicetrapib | Brazil | BR112017002873 | 2034-08-12 | ⤷ Sign Up |
| Obicetrapib | Canada | CA2958040 | 2034-08-12 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
